EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
EC grants conditional marketing authorization based on the EFFISAYIL trial
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Asia’s premier and USA-patented, ANSSI Wellness for spinal decompression was launched in Pune
It offers quick relief in various types of Coughs, Colds and Sore Throat,
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
